One Pager as on October 31, 2022
Selection of focused sustainable businesses from across sectors | |
Potential to generate higher risk adjusted returns in the long term | |
Active management of portfolio with primary investments in mid-caps | |
Data as on October 31, 2022
Sector | MMMUY | Nifty Midcap 150 TRI |
Financial Services | 16.46% | 18.46% |
Capital Goods | 14.42% | 12.38% |
Automobile And Auto Components | 10.65% | 8.54% |
Chemicals | 8.24% | 7.42% |
Healthcare | 6.13% | 10.36% |
Data as on October 31, 2022
Security | % to Net Assets |
The Federal Bank Limited | 3.71% |
Aditya Birla Fashion and Retail Limited | 3.07% |
Infosys Limited | 2.99% |
Abbott India Limited | 2.92% |
Bank of Baroda | 2.72% |
Cummins India Limited | 2.68% |
Persistent Systems Limited | 2.61% |
Max Healthcare Institute Limited | 2.57% |
Grindwell Norton Limited | 2.52% |
Oberoi Realty Limited | 2.42% |
Top 10 Holdings | 28.20% |
Fresh Additions | Complete Exits |
Security | Security |
Bharat Forge Limited | Alkem Laboratories Limited |
IDFC Limited | Arvind Limited |
IPCA Laboratories Limited | Ashok Leyland Limited |
NMDC Limited | Fortis Healthcare Limited |
NMDC Steel Limited | Jindal Steel & Power Limited |
TVS Motor Company Limited | National Aluminium Company Limited |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant portfolio changes during the month and should not be construed as recommendation to buy/sell/ hold. The fund manager may or may not choose to hold these companies/stocks, from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s).
Data as on October 31, 2022
Turnover Ratio (Last 1 year) | 1.18 |
Standard Deviation | 21.97% |
Beta1 | 0.79 |
Sharpe Ratio# | 0.74 |
Jenson's Alpha2 | -0.0097 |
#Risk-free rate assumed to be 6.25% (MIBOR as on 31-10-22) - Source: www.mmda.org
1. Beta is calculated on the basis of average monthly rolling returns as of last day of the month since inception till October 31, 2022 and annualized. 2. Calculated for the period since inception till October 31, 2022. | Data Source: ICRA Analytics, Bloomberg | Data as on October 31, 2022 | N.A.: Net Assets
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 30-Jan-18.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period. Mr. Abhinav Khandelwal is managing this fund since February 1, 2022. Mr. Manish Lodha is managing this fund since December 21, 2020.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 30-Jan-18.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. The performance details provided above are of Growth Option under Regular Plan Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Abhinav Khandelwal manages 5 schemes and
Mr. Manish Lodha manages 9 schemes of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Performance as on October 31, 2022
This product is suitable for investors who are seeking*:
• Long term capital appreciation;
• Investment predominantly in
equity and equity related securities
including derivatives of mid cap
companies.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.